H3P37: A Potential Drug Target for Cancer (G664611)

Target Name: H3P37

NCBI ID: G664611

H3P37

Other Name(s): H3F3AP2 | H3 histone pseudogene 37 | H3F3CP | p47

H3P37: A Potential Drug Target for Cancer

H3P37, also known as H3F3AP2, is a protein that is expressed in various tissues throughout the body. It is a key regulator of the cell cycle, which plays a critical role in the development and progression of cancer. Therefore, H3P37 has been identified as a potential drug target or biomarker for cancer treatment.

The cell cycle is the process by which a cell grows, replicates its DNA, and divides. The cell cycle is regulated by a complex network of proteins, including H3P37. H3P37 is a key regulator of the G1 phase of the cell cycle, which is the phase when the cell prepares for cell division.

During the G1 phase, H3P37 plays a critical role in regulating the growth and replication of the cell's DNA. It does this by controlling the activity of several key enzymes that are involved in the cell cycle. For example, H3P37 can inhibit the activity of the protein kinase kinase (PKG), which is involved in the metaphase of the cell cycle. This means that H3P37 can prevent the cell from entering the metaphase stage and begin to divide.

H3P37 can also inhibit the activity of the protein tyrosine phosphatase (PTP), which is involved in the G1 phase. This means that H3P37 can prevent the phosphatase from breaking down tyrosine, which is a protein that is involved in cell signaling.

In addition to inhibiting the activity of PKG and PTP, H3P37 can also activate the activity of several other enzymes that are involved in the cell cycle. For example, H3P37 can activate the activity of the GTPase-activating protein (GAP), which is involved in the G1 phase. This means that H3P37 can cause the cell to enter the G2 phase and prepare for cell division.

H3P37's role in the cell cycle is important for the development and progression of cancer. Many studies have shown that H3P37 is often overexpressed or hyperactive in cancer cells. This means that the level of H3P37 in the cells is higher than in healthy cells, and it can contribute to the growth and survival of the cancer cells.

H3P37 has also been identified as a potential biomarker for cancer. This is because its expression is often increased in cancer cells, and it can be used as a target for cancer therapies. For example, drugs that inhibit the activity of H3P37 have been shown to be effective in treating various types of cancer.

In conclusion, H3P37 is a protein that plays a critical role in the regulation of the cell cycle and has been identified as a potential drug target or biomarker for cancer treatment. Its role in the cell cycle is important for the growth and survival of cancer cells , and it has also been shown to be an effective target for cancer therapies. Further research is needed to fully understand the role of H3P37 in cancer and to develop effective treatments.

Protein Name: H3 Histone Pseudogene 37

The "H3P37 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about H3P37 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets